Winds of change in Sun Pharma’s $11.75 billion Organon acquisition announcement & more related News Here

Sun Pharmaceutical Industries on Monday announced the $11.75 billion acquisition of Organon & Co, an aggressive move into the US market, which has long decided the global fortunes of Indian drugmakers. However, the biggest purchase by an Indian company in nearly 20 years also signals that the decades-long allure of the US generics market is beginning to fade for Indian drugmakers, who are now eyeing new markets like China, South Korea and Spain with branded generics.

Announced early Monday, the Organon acquisition is the second-largest by an Indian company, after Tata Steel’s 2007 deal to buy British steelmaker Corus Group for $12 billion.

For years, Indian pharma rode a powerful wave in the US, as expiring patents on blockbuster small-molecule drugs opened up a gold mine for low-cost generic drugmakers in the world’s largest drug market. Companies like Dilip Shanghvi-led Sun Pharma built scale, profitability and global credibility by entering the US. Even today, the US contributes about 31% of flax’s revenues, second only to the Indian domestic market at 37%.

The purchase of Organon subtly but significantly changes that balance – once the deal closes, India’s share of Sun Pharma-Organon’s combined $12.4 billion revenue drops to 17%, while the US share stands at 27%. In absolute terms, US revenues would increase from $1.9 billion to $3.35 billion, or an incremental $1.4 billion. Organon’s revenue in 2025 was $6.2 billion.

Also read: Indian pharma set to boost generic strength as patent for Ozempic, Vegovy expires today

This mismatch underlines the real intention of the deal – Shanghvi is not paying a premium to double down on the US. Industry experts and analysts said it is buying access to markets, portfolios and new therapeutic segments beyond that.

According to Kiran Ganorkar, managing director of Sun Pharma, the real value lies in geographical diversification. It opened markets such as Korea where Sun had little or no presence, and strengthened its foothold in regions such as China and Spain, where Organon already had scale.

Bino Pathiparampil, head of research at Elara Capital, said in a report that the acquisition improves Sun’s penetration in select large markets such as China and South Korea.

China, in particular, stands out as a strategic prize. In a statement, Sun’s Ganorkar called it an “untapped $150 billion opportunity,” and the buyout provides Sun with a ready platform to participate in that growth. More broadly, Sun and Organon’s complement portfolios, particularly in branded generics, create opportunities for cross-selling in many regions, said an industry executive on condition of anonymity.

Also read: Sun Pharma to buy US-based oncology firm with new skin cancer treatment product for $355 million

This change comes at a time when the US generics market is no longer the reliable growth engine it once was. Pricing pressures have intensified, competition has increased, and consolidation among buyers has squeezed margins. What was once a high-growth, high-margin opportunity has become increasingly commoditized. Geopolitical risks, including threats of tariffs on pharmaceutical imports, are also adding to uncertainty, which has made exporters wary of excessive exposure to the single market.

American opportunity has also changed at the structural level. The era of frequent blockbuster patent expirations in small-molecule drugs is waning. Innovation is moving towards biologics and specialty therapies – segments that are more complex, capital-intensive and less accessible to traditional generic players. For Indian companies, this means fewer easy wins in their most important export market.